

1 **HIV-1 latency reversal agent boosting is not limited by opioid use**

2
3 Tyler Lilie¹†, Jennifer Bouzy¹†, Archana Asundi², Jessica Taylor^{2,3}, Samantha Roche², Alex
4 Olson², Kendyll Coxen¹, Heather Corry¹, Hannah Jordan¹, Kiera Clayton⁴, Nina Lin²‡, Athe
5 Tsibris^{1,5}‡*

6 † These authors contributed equally to this work

7 ‡ These authors contributed equally to this work

8

9 **Affiliations:**

10 ¹Brigham and Women’s Hospital, Boston, MA, USA.

11 ²Department of Medicine, Boston University School of Medicine & Boston Medical
12 Center, Boston, MA USA.

13 ³Grayken Center for Addiction, Boston Medical Center, Boston, MA USA.

14 ⁴Department of Pathology, University of Massachusetts T.H. Chan School of Medicine,
15 Worcester, MA, USA.

16 ⁵Harvard Medical School, Boston, MA, USA.

17 *Correspondence: atsibris@bwh.harvard.edu

18

19 **Short title:** Opioid use effects on novel HIV-1 latency reversal

20

21

22 **Abstract**

23 The opioid epidemic may impact the HIV-1 reservoir and its reversal from latency in virally
24 suppressed people with HIV (PWH). We studied forty-seven PWH and observed that lowering
25 the concentration of HIV-1 latency reversal agents (LRA), used in combination with small
26 molecules that do not reverse latency, synergistically increases the magnitude of HIV-1 re-
27 activation *ex vivo*, regardless of opioid use. This LRA boosting, which combines a Smac mimetic
28 or low-dose protein kinase C agonist with histone deacetylase inhibitors, can generate
29 significantly more unspliced HIV-1 transcription than phorbol 12-myristate 13-acetate (PMA)
30 with ionomycin (PMAi), the maximal known HIV-1 reactivator. LRA boosting associated with
31 greater histone acetylation in CD4⁺ T cells and modulated T cell activation-induced markers and
32 intracellular cytokine production; Smac mimetic-based boosting was less likely to induce
33 immune activation. We found that HIV-1 reservoirs in PWH contain unspliced and
34 polyadenylated (polyA) virus mRNA, the ratios of which are greater in resting than total CD4⁺ T
35 cells and can correct to 1:1 with PMAi exposure. Latency reversal results in greater fold-change
36 increases to HIV-1 poly(A) mRNA than unspliced message. Multiply spliced HIV-1 transcripts
37 and virion production did not consistently increase with LRA boosting, suggesting the presence
38 of a persistent post-transcriptional block. LRA boosting can be leveraged to probe the
39 mechanisms of an effective cellular HIV-1 latency reversal program.

40

41

42

43

44

45 **Introduction**

46 HIV-1 proviral DNA remains integrated in CD4⁺ T cells during suppressive antiretroviral
47 therapy (ART) and is a barrier to cure. This virus reservoir, defined as cells that contain provirus
48 capable of generating infectious virions, is initially seeded within days of infection before
49 symptoms develop (1, 2), persists (3-5), decays slowly (6), and can be maintained indefinitely (7,
50 8). The best approach to pursue HIV eradication remains uncertain. One strategy aims to
51 pharmacologically reactivate latent HIV transcription in the setting of suppressive ART, induce
52 virus protein production in infected cells, and then clear the reservoir through immune-mediated
53 mechanisms (9-11). HIV-1 latency reversal agents (LRA) have advanced into clinical trials as
54 monotherapy but with modest results; transient increases in virus cell-associated RNA (caRNA)
55 production may be observed with some LRA but does not translate into a decrease in reservoir
56 size (12-22). HIV-1 latency may be characterized by transcriptional blocks that cannot be
57 overcome by single LRA (23-26).

58 To address these limitations, novel classes and combinations of LRA have been studied
59 (27). Epigenetic LRA such as histone deacetylase inhibitors, when combined with protein kinase
60 C agonists or second mitochondria-derived activator of caspase (Smac) mimetics, have been
61 reported under some conditions to synergistically increase HIV-1 transcription in CD4⁺ T cells
62 isolated from virally suppressed participants with HIV (28-32). Generally, the sample sizes were
63 small and evaluated LRA concentrations in the mid-nanomolar to micromolar range. The
64 absolute amount of HIV-1 latency reversal reported with combination LRA, defined primarily as
65 induced levels of HIV-1 caRNA, has been significantly less than that observed with the maximal
66 HIV-1 reactivating combination of phorbol 12-myristate 13-acetate (PMA) and ionomycin

67 (PMAi). A trade-off may exist between maximum synergy and maximum efficacy in
68 combination LRA approaches (33).

69 While HIV-1 is generally accepted to be transcriptionally silent during suppressive ART,
70 this latency may not be absolute. Studies demonstrate that short promoter proximal transcripts of
71 less than 60 nucleotides may be generated in the absence of the HIV-1 trans-activator of
72 transcription protein, Tat (34, 35). More recently, resting CD4⁺ T cells isolated from PWH were
73 found to contain transcripts extending beyond the transcriptional pausing site, a minority of
74 which may be full-length or spliced and polyadenylated (36). Total CD4⁺ T cells isolated from
75 PWH may contain approximately sevenfold more proximal HIV-1 transcripts, of at least 185
76 nucleotides in length, than polyadenylated virus mRNA (23). HIV-1 cell-associated RNA is
77 readily detectable in the blood and tissue of PWH on virologically suppressive ART (37-40).

78 People with HIV may be exposed to opioids, whether prescribed for chronic pain (41),
79 prescribed for opioid use disorder (42), or injected as heroin (43). The pharmacology of opioids
80 associated with substance use disorders may differ from opioid medications used to treat chronic
81 pain. The μ opioid agonists, e.g. heroin, fentanyl, morphine, and methadone, can block IL-2
82 mRNA and protein production in activated T cells through inhibition of AP-1, NFAT, and NF-
83 κ B activation, transcription factors known to be positive regulators of HIV transcription
84 initiation (44-46). The effects of buprenorphine, a partial μ opioid agonist and κ and δ opioid
85 antagonist commonly used in the treatment of opioid use disorder, on HIV-1 latency and its
86 reversal have not been explored. A recent finding suggested that people with HIV who use
87 opioids may have diminished responses to latency reversal mediated by T cell receptor (TCR)
88 agonism (47).

89 To investigate the mechanisms that control HIV-1 latency reversal during opioid use, we
90 enrolled a cohort of thirty-six treated, virologically suppressed participants with HIV. We
91 originally hypothesized that opioid use would limit HIV-1 latency reversal and vary as a function
92 of opioid use type. We tested LRA combinations at concentrations lower than those typically
93 assessed and identified the phenomenon of LRA boosting: synergistic HIV-1 transcriptional
94 reactivation with small molecules that do not reverse latency as single agents. We corroborated
95 these findings in an additional eleven participants from a separate cohort and identified key
96 associations between potent LRA boosting, increases in histone acetylation, modulation of T cell
97 phenotype and function, and downstream blocks to virion production. While benchmarking LRA
98 boosting, we observed that HIV-1 transcription during treated infection may be greater than
99 previously appreciated and varies by CD4⁺ T cell phenotype. Importantly, we find that opioid
100 use did not limit the magnitude or mechanisms of LRA boosting.

101

102

103

104

105

106

107

108

109

110 **Results**

111 **Opioid use does not affect HIV-1 reservoir size**

112 We enrolled the Opioids, HIV, and Translation (OPHION) cohort from a single academic
113 center of thirty-six virally suppressed participants with HIV who used, or did not use, opioids in
114 a 2:1 ratio. Participants had a median age of 59 years, included one-third women, and were
115 approximately 30% white (**Table 1**). The median duration of ART was 12 years with a median
116 duration of undetectable plasma HIV-1 RNA levels of over six years. Participant characteristics
117 were further defined by type of opioid use (**Suppl. Table 1**) and validated by urine toxicology
118 and self-reported substance use questionnaires (**Suppl. Fig. 1**). To reflect the range of opioid use
119 encountered in clinical practice, this cohort comprised participants who actively injected opioids
120 (n=4), used methadone (n=4) or suboxone (n=12) as medication for opioid use disorder, or took
121 opioids for chronic pain (n=4). Amphetamine and barbiturate use were not detected. All active
122 injection opioid users had confirmatory urine toxicology screens positive for fentanyl (n=2 of 4,
123 range 62 - >500 ng/mL) and/or norfentanyl (n=4 of 4 participants, range 46 - >500 ng/mL) and
124 reported a median of 6 days of injection opioid use in the preceding 30 days (IQR 4-16 days)
125 with a median of 7 days since the most recent use (IQR 4-14 days). All participants in the
126 methadone, buprenorphine, and prescription opioid subgroups had urine toxicology positive for
127 that substance.

128 To assess markers of HIV-1 persistence, we quantified total HIV-1 DNA and caRNA in
129 PBMC and evaluated intact proviral reservoir size (**Fig. 1**). Total HIV-1 DNA levels were
130 statistically similar between opioid and non-opioid groups, 2.36 vs 2.38 log₁₀ copies/10⁶ PBMC,
131 respectively, as were HIV-1 caRNA levels, 2.45 vs 2.52 log₁₀ copies/10⁶ PBMC (**Fig. 1a**).
132 Levels of intact provirus DNA were also similar between groups, 2.00 vs 1.82 log₁₀ copies/10⁶

133 **Table 1. OPHION Participant Characteristics**

Characteristic	Cohort		Total*
	Non-Opioid	Opioid	
Participants, N	12	24	36
Age			
Median (IQR) [†]	56 (50-61)	61 (55-65)	59 (54-65)
Sex			
Male N (%)	7 (58%)	17 (71%)	24 (67%)
Race			
Black N (%)	10 (83%)	6 (25%)	16 (44%)
White N (%)	2 (17%)	9 (38%)	11 (31%)
Hispanic/Latino** N (%)	0	2 (8%)	2 (6%)
American Indian N (%)	0	1 (4%)	1 (3%)
Declined/NA	0	6 (25%)	6 (17%)
Ethnicity			
Non-Hispanic N (%)	11 (92%)	13 (54%)	24 (67%)
Hispanic N (%)	1 (8%)	11 (46%)	12 (33%)
Duration of ART (months)			
Median (IQR)	162 (106-204)	136 (91-173)	144 (97-179)
Duration of viral suppression (months)			
Median (IQR)	69.5 (38-91)	79 (51-94)	75 (44-93)

134 *Percentage totals may not add up to 100 due to rounding. [†]IQR, interquartile range. ** Participants may
 135 identify as Hispanic/Latino either in response to a question about their race, or a follow-up question on
 136 ethnicity. Participants who reported Hispanic ethnicity identified their race as either “White” or
 137 “Declined/Not Available.”

138

139

140

141 PBMC. To better define the intact proviral DNA reservoir, we characterized 5' and 3' HIV-1
142 deletions across cohorts and opioid use subgroups (**Fig. 1b-c**). Similar proportions of intact 5'
143 and 3' genetic regions were observed, irrespective of opioid use. The ratios of proviruses
144 containing an intact 5' region and a defective (hypermutated) or deleted 3' region in HIV-1 *env*
145 were statistically similar. An exploratory analysis demonstrated a greater proportion of total
146 genomes were intact in active injection opioid users, although this result was not significant
147 when adjusted for multiple comparisons (**Fig. 1d**).

148

149 **LRA boosting markedly increases HIV-1 transcription**

150 To determine the effects of opioid use on HIV-1 latency reversal *ex vivo*, we isolated
151 PBMC from thirty-six participants enrolled in the OPHION cohort and tested a panel of ten LRA
152 conditions (**Fig. 2**). The histone deacetylase inhibitors (HDACi) romidepsin (RMD) and
153 panobinostat (PNB) were used at the lowest concentrations most commonly reported in the
154 literature and the protein kinase C agonist bryostatin was tested at 1nM, one-tenth the most
155 commonly reported concentration. In single LRA conditions, we observed a 2.7-fold activation
156 of HIV-1 caRNA transcription, relative to an untreated DMSO-containing control, with anti-
157 CD3/anti-CD28 (α CD3/ α CD28) beads, a T cell receptor (TCR) agonist (**Fig. 2a**). This
158 magnitude of TCR agonism-induced latency reversal is consistent with prior studies (23, 48-52).
159 Statistically greater reactivation was observed with RMD (3.8-fold increase) when compared to
160 PNB (2.6-fold increase) (**Suppl File 1**). Low-dose bryostatin minimally increased unspliced
161 HIV-1 caRNA levels (1.2-fold increase), but the Smac mimetic AZD5582 (AZD), at a standard
162 concentration (53), did not (0.9-fold increase, 95% CI [0.8, 1.1]).

163 We next assessed LRA in combination. Incubation of PBMC with HDACi and either
164 AZD or low-dose bryostatin potentiated HIV-1 latency reversal. AZD in combination with PNB
165 or RMD increased HIV-1 caRNA levels 8.1-fold and 9.1-fold, respectively. Low-dose bryostatin
166 with PNB increased HIV-1 caRNA 10.6-fold, whereas the greatest fold-induction of HIV-1
167 caRNA was observed with the combination of low-dose bryostatin and RMD (13.2-fold).
168 Statistically greater HIV-1 RNA induction was observed with the LRA boosting combinations
169 relative to HDACi monotherapy and TCR agonism, when corrected for multiple comparisons.
170 We compared LRA response as a function of opioid use (**Fig. 2b**), sex (**Fig. 2c**), race (**Fig. 2d**),
171 and ethnicity (**Suppl. Fig. 2a**) and observed no statistically significant differences in the fold-
172 changes of HIV-1 caRNA induction across these groups. In an exploratory analysis, the fold-
173 change in HIV-1 caRNA varied by opioid use subgroup in response to T cell receptor agonism
174 (**Suppl Fig 2b**). Statistically significantly greater reactivation with α CD3/ α CD28 beads was
175 observed in the suboxone sub-group when compared to active injection opioid users, the group
176 with the smallest fold-change in TCR agonism-induced HIV-1 caRNA levels.

177

178 **LRA boosting modulates T cell activation and cytokine production**

179 To understand whether LRA boosting activates CD4⁺ T cells, we assessed the
180 upregulation of surface activation-induced markers (AIM) (54). We leveraged dual-marker AIM
181 assays (**Suppl. Fig. 3, Fig. 3a**), originally developed to detect T cell antigen responsiveness, to
182 quantify cellular activation that occurs with LRA exposure, outside the context of peptide-
183 specific recognition. Using TCR agonism as a positive control, responses were detected in 49%,
184 32%, and 42% of CD4⁺ T cells in the OX40/PDL1, OX40/CD25, and CD69/CD40L AIM assays,
185 respectively (**Fig. 3b**). Low-dose bryostatin significantly upregulated surface expression to more

186 modest levels in all three AIM assays, relative to an untreated control condition. Bryostatin
187 induced OX40/PDL1 surface expression in 5.2% of CD4⁺ T cells, levels of induction that did not
188 significantly change when used in combination with RMD (5.4%) or PNB (3.5%). Bryostatin
189 monotherapy induced expression in 6.9% and 2.6% of CD4s in the OX40/CD25 and
190 CD69/CD40L AIM assays, respectively. In these two assays, the combination of RMD or PNB
191 with low-dose bryostatin significantly reduced activation-induced markers, relative to bryostatin
192 alone, and in some cases to control (untreated) levels; these findings did not differ by opioid use
193 (**Suppl. Fig. 4a-c**). The remainder of the LRA panel and their combinations did not upregulate
194 surface expression in any AIM assay.

195 We observed a more pronounced upregulation in isolated CD69 expression, an early
196 activation marker, in response to LRA. Approximately 0.5% of untreated CD4⁺ T cells expressed
197 CD69 after 18 hours in culture (**Fig. 3c**). The proportion of cells expressing surface CD69
198 significantly increased to similar levels with TCR agonism (68.5%) and low-dose bryostatin
199 (72.9%). Whereas AZD5582 (1.0%), RMD (4.7%), and PNB (5.4%) modestly increased CD69
200 levels, combinations of these small molecules led to synergistic effects. Significantly greater
201 induction of CD69 expression was observed when RMD or PNB was combined with bryostatin
202 or AZD5582; a bryostatin combination induced more CD69 than an HDACi plus AZD5582.
203 CD69 levels were statistically similar when comparing TCR agonism, bryostatin alone, and
204 bryostatin in combination with either HDACi (**Suppl. Fig. 4d**).

205 To further probe LRA effects on T cell activation, we stained CD4⁺ (CD4s) and CD8⁺ T
206 cells (CD8s) for intracellular cytokine production (**Fig. 3d-e**). Whereas cytokine assessments in
207 T lymphocytes most commonly include IL-2 and IFN- γ , we additionally quantified intracellular
208 TNF- α by flow cytometry. We observed a cytokine production hierarchy in CD4s, where the

209 levels were $\text{TNF-}\alpha > \text{IL-2} > \text{IFN-}\gamma$, and in CD8s, where $\text{TNF-}\alpha > \text{IFN-}\gamma > \text{IL-2}$. In response to
210 TCR agonism, significantly more CD4s produce $\text{TNF-}\alpha$ (30.4%) than IL-2 (14.3%) or IFN- γ
211 (6.0%), and significantly more IL-2 than IFN- γ (**Suppl. Fig. 4e**). We identified a different
212 hierarchy in CD8⁺ T cells (CD8s), where the proportion of cells producing $\text{TNF-}\alpha$ remained
213 greatest (17.5%) but significantly more IFN- γ (9.0%) was produced compared to IL-2 (4.3%).
214 Whereas HDACi monotherapy did not increase the proportion of CD4s or CD8s producing
215 cytokines compared to an untreated control, low-dose bryostatin alone or in combination with
216 HDACi significantly increased production of $\text{TNF-}\alpha$ and, to a smaller magnitude, IFN- γ in
217 CD4s. Significantly more CD4s produced $\text{TNF-}\alpha$ than IFN- γ in response to RMD + bryostatin
218 (4.5% versus 1.3%) and PNB + bryostatin (4.2% versus 1.7%) (**Suppl. File 1**). In CD8s, low-
219 dose bryostatin significantly increased production of $\text{TNF-}\alpha$ (2.8%) and IFN- γ (1.5%). The
220 proportions of CD8s that produced $\text{TNF-}\alpha$ and IFN- γ when exposed to the combinations of RMD
221 + bryostatin (3.4% versus 4.7%) and PNB + bryostatin (4.1% versus 4.6%) were similar and
222 were statistically similar to bryostatin alone. IL-2 production did not increase above 0.1% of
223 CD4s or CD8s for any LRA, or combination, we tested.

224

225 **LRA boosting increases histone acetylation**

226 To investigate the mechanism(s) of LRA boosting, we next assessed histone acetylation.
227 The proportions of acetylated histone H3⁺ live CD4s were similar between untreated cells
228 (19.7%) and cells exposed to RMD (21.8%), PNB (21.7%), or AZD (19.8%) and significantly
229 increased after single-LRA exposure to $\alpha\text{CD3}/\alpha\text{CD28}$ beads (35.5%) and low-dose bryostatin
230 (29.2%) (**Fig. 4a**). Low-dose bryostatin in combination with either RMD (36.8%) or PNB
231 (37.5%) significantly increased the proportions of CD4s contained acetylated histone H3.

232 Interestingly, statistically significant increases in the proportions of acetylated histone H3⁺ live
233 CD4s were also observed when combining LRA which individually did not affect these
234 percentages, specifically RMD + AZD (30.0%) and PNB + AZD (29.8%). These results did not
235 differ by opioid use (**Suppl. Fig 5a**).

236 Levels of acetylated histone H3, measured by median fluorescence intensity (MFI), were
237 similar in untreated live CD4s and in cells cultured with α CD3/ α CD28 beads, low-dose
238 bryostatin, or AZD (**Fig. 4b**). Significant 3.4-fold and 3.3-fold increases in acetyl histone MFI
239 were observed for RMD and PNB, respectively. AZD in combination with RMD or PNB further
240 increased MFI by 6.1- fold and 5.7-fold, respectively. Absolute increases in MFI were observed
241 for low-dose bryostatin in combination with RMD or PNB but did not retain significance after
242 correction for multiple comparisons. These results did not differ by opioid use (**Suppl. Fig 5b**).
243 We observed no association between acetylated histone H3 MFI and fold-change in HIV-1 RNA
244 levels for HDACi monotherapy or for HDACi in combination with AZD (**Fig 4c-d**). A
245 statistically significant weak association between the proportion of acetyl histone H3⁺ CD4s and
246 fold-change in HIV-1 RNA levels was detected for HDACi in combination with bryostatin (**Fig**
247 **4e**).

248

249 **LRA boosting does not consistently induce virion production**

250 To extend our analyses from the OPHION cohort, we next studied an additional eleven
251 participants with HIV who did not use opioids, enrolled in the HEAL cohort, for whom
252 leukapheresis samples were available (**Supplementary Table 2**). We compared LRA boosting
253 responses in PBMC to the most potent known HIV-1 LRA, PMA in combination with ionomycin
254 (PMAi). Significant fold-change increases in HIV-1 transcription were observed with

255 combinations of low-dose bryostatin with RMD (8.3-fold) or PNB (8.0-fold), when compared to
256 RMD alone (3.4-fold), PNB alone (3.1-fold), or PMAi (1.6-fold) (**Fig. 5a**). In separate
257 experiments, we observed statistically similar HIV-1 transcription with an HDACi in
258 combination with AZD, relative to PMAi (**Fig 5b**). No significant increases in HIV-1
259 transcription were observed in PBMC experiments with low-dose bryostatin (1.0-fold, 95% CI
260 0.9, 1.1) or AZD (1.2-fold, 95% CI 0.6, 1.9). Similar magnitudes of HIV-1 transcriptional
261 reactivation were seen with HDACi monotherapy, low-dose bryostatin, and AZD monotherapy
262 across the OPHION and HEAL cohorts we studied. We evaluated human reference gene
263 transcription per million PBMC during LRA treatment and observed decreases with HDACi
264 exposure, increases with PMAi, and variable changes with bryostatin (**Suppl. Fig. 6**) (37, 55).

265 To assess the magnitude of HIV-1 latency reversal as a function of cell type, we next
266 performed parallel experiments in PBMC and total CD4⁺ T cells (**Fig. 5c**). While CD4⁺ T cells
267 are the only established HIV-1 reservoir in PBMC, we performed this comparison across cell
268 types to increase experimental rigor. Levels of HIV-1 caRNA were, on average, 4.3-fold higher
269 (range 3.2 – 6.0) across experimental conditions performed in CD4⁺ T cells, when compared to
270 PBMC, and varied by 1.6 log₁₀ (PBMC) and 1.8 log₁₀ (CD4) across participant samples in the
271 absence of LRA exposure. To control for absolute caRNA differences, we determined fold-
272 changes in LRA response and observed statistically significant increases in HIV-1 caRNA with
273 low-dose bryostatin in combination with RMD or PNB, when compared to PMAi, in both PBMC
274 and CD4s (**Fig. 5d**). To explore the variance in LRA response, we compiled per-participant
275 biological replicate measurements (**Suppl. Fig. 7a**). Supernatant HIV-1 RNA levels increased
276 after 24hr incubation of PBMC with PMAi (19 copies/mL, 95% CI [10, 32]) and the
277 combinations of RMD plus bryostatin (27 copies/mL, 95% CI [11, 34]) or AZD (31 copies/mL,

278 95% CI [14, 43]), and PNB plus bryostatin (35 copies/mL, 95% CI [19, 60]) or AZD (12
279 copies/mL, 95% CI [8.1, 26]), when compared to untreated PBMC (3.0 copies/mL, 95% CI [2.2,
280 6.9]), but these results were not statistically significant after correction for multiple comparisons
281 (**Fig. 5e**). This virion production response was dichotomized by participant. For each LRA
282 condition, PBMC samples from at least 5 of 10 participants showed no increases in HIV-1 RNA
283 levels over control; these were most commonly the same participants. Additionally, no
284 significant increases in LRA-induced virion production in isolated CD4⁺ T cell cultures were
285 observed. Greater virion production in untreated CD4s and greater absolute magnitudes of LRA-
286 associated supernatant viremia in CD4s were noted, relative to PBMC, but these increases were
287 seen in only a subset of participants. To define this post-transcriptional block more precisely, we
288 quantified the frequency of CD4s with inducible multiply spliced HIV-1 RNA transcripts (**Fig.**
289 **5f**) (56). No significant increases in the frequency of cells that contain HIV-1 *tat/rev* transcripts
290 were observed with RMD in combination with bryostatin at either 1nM or 10nM concentrations.
291 In a post-hoc analysis, we combined datasets from OPHION and HEAL participants, including
292 LRA conditions common to both sets of experiments, and observed statistically significant
293 increases in HIV-1 unspliced RNA transcription with all LRA boosting combinations (**Fig. 5g,**
294 **Suppl. Fig 7b**). The variance in LRA response, defined by the interquartile range, increased as
295 the magnitude of fold change in HIV-1 caRNA increased.

296

297 **Effective latency reversal normalizes unspliced:polyadenylated HIV-1 mRNA ratios**

298 We observed lower PMAi-associated fold-changes in HIV-1 caRNA levels with our unspliced
299 HIV-1 RNA qPCR assay when compared to prior studies that quantified poly-adenylated
300 (poly(A)) HIV-1 mRNA (28, 32). These assays differ methodologically and so we directly

301 compared them and assessed the effects of primer location, CD4⁺ T cell phenotype, and CD4⁺ T
302 cells density on HIV-1 caRNA quantifications (**Fig. 6a**). In response to a 24-hour PMAi
303 exposure, levels of HIV-1 unspliced caRNA increased 4.3 – 8.6-fold. These levels did not
304 significantly differ between resting (rCD4, CD25⁻CD69⁻HLA-DR⁻) and total CD4⁺ T cell (tCD4)
305 stimulations, nor when CD4⁺ T cells were cultured at densities of 5x10⁶ or 1x10⁶ cells/mL.
306 Poly(A) HIV-1 caRNA levels increased 32-34-fold with the same PMAi stimulation and were
307 statistically significantly greater than unspliced HIV-1 caRNA fold-changes for each input CD4⁺
308 T cell phenotype or cell density. While PMAi-induced fold-changes in HIV-1 RNA were similar
309 between rCD4 and tCD4, we observed differences in the amounts of unspliced and
310 polyadenylated message present in these untreated cell populations. In the absence of LRA
311 treatment, significantly greater ratios of unspliced to poly(A) HIV-1 caRNA were seen in rCD4
312 (10.6-13.3), relative to tCD4 (2.8-3.5) (**Fig 6b**). The differences in these ratios were driven by
313 differences in HIV-1 poly(A) transcript levels. While untreated rCD4 and tCD4 at 5 million or 1
314 million cells/mL contained similar absolute levels of unspliced HIV-1 caRNA transcripts
315 (p=0.98 for each), untreated tCD4 demonstrated statistically greater copy numbers of HIV-1
316 poly(A) mRNA per million CD4s (p<0.005 at 5m cells/mL, p<0.001 at 1mL cells/mL, Freidman
317 test (ANOVA) with Dunn's correction for multiple comparisons; **Suppl File 1**). PMAi
318 stimulation normalized unspliced:poly(A) ratios to 1.7-2.4 in rCD4 and 0.8-1.0 in tCD4s (**Fig 6c,**
319 **d**). Significantly lower ratios of unspliced:poly(A) HIV-1 RNA were observed in reactivated
320 tCD4, when compared to rCD4 (**Fig. 6e**).

321

322

323

324 **Discussion**

325 An approach to cure HIV infection should be equally effective for all people. Here we
326 explored how opioid use may affect our ability to reverse HIV-1 latency. Opioid use is complex
327 and can be accompanied by comorbidities, such as immune activation with injection drug use
328 (57, 58), that may impact the HIV-1 reservoir and its persistence (37, 59-62). Here we found no
329 effects of opioid use by indication, type, or pharmacology on markers of HIV-1 persistence. In
330 the setting of persistently suppressed viremia, opioid use was less likely to modulate virus
331 reservoir size, findings that agree with recent studies of injection heroin use (47, 63). Overall,
332 participants were matched on the duration of ART and virus suppression, key variables that have
333 been associated with HIV-1 reservoir size (64), and our urine toxicology results were consistent
334 with the participants' ascribed opioid use group.

335 We used samples from opioid users to identify the phenomenon of LRA boosting:
336 improving the potency of HDACi beyond that of PMA-ionomycin by combining with a 2nd drug
337 that does not, by itself, re-activate HIV-1 transcription. This boosting occurred at lower LRA
338 concentrations, here at least half the RMD, 1/10th the bryostatin, and 1/100th the Smac mimetic
339 concentrations used in prior combination studies (28-31). Synergistic latency reversal effects of
340 low-dose bryostatin (1nM) and romidepsin was previously identified in samples from four
341 participants with HIV (28). Here we leveraged samples from forty-seven participants to confirm
342 those findings, extend the observation to HDACi in combination with low-dose bryostatin more
343 generally, and to LRA boosting with a Smac mimetic. A recent study identified that injection
344 opioid use was associated with a lack of ex vivo HIV-1 activation to TCR agonism (47). and our
345 findings in the subgroup of active injection opioid users agree with this. However, this
346 observation did not extend to other types of opioid use, e.g. suboxone use. Additional studies are

347 needed to corroborate these findings in a larger sample size and investigate why HIV-1 latency
348 reversal by TCR agonism may be particularly affected by injection opioids.

349 While AZD5582 has been reported to induce virus transcription, we observed no HIV-1
350 latency reversal activity when used as a single agent in PBMC isolated from the 47 participants
351 we tested. AZD5582 monotherapy has been assessed for human ex vivo HIV-1 latency reversal
352 activity in four prior studies, using the endpoints of a quantitative virus outgrowth assay, HIV-1
353 cell-associated RNA levels, and HIV-1 p24 production. In these studies, QVOA and p24
354 responses were not observed in the majority of participants, HIV-1 *gag* caRNA increases were
355 approximately 2-fold, and the statistical significance of the results was less clear (53, 65, 66).
356 Our findings agree more with a recent study that assessed AZD5582 monotherapy and did not
357 identify HIV-1 LRA activity (32).

358 Our relatively large sample size, for this field, allowed us to determine that LRA boosting
359 was less likely to be affected by sex, race, or ethnicity. We do note, however, that non-opioid
360 participants in both our OPHION and HEAL cohorts were more likely to be black, whereas
361 participants who used opioids were a more racially and ethnically mixed population. The use of
362 two HDACi in our panel of ten LRA conditions increased the generalizability of the findings we
363 observed with this drug class. Similar magnitudes of boosting were observed with RMD and
364 PNB and suggests that class I histone deacetylase inhibition may be more relevant to this
365 phenomenon (67, 68). HDACi-induced changes in acetylated histone (AcH) H3 and/or H4 are
366 nearly exclusively reported in the literature as changes in MFI (13, 16-19, 69-72), not as a
367 function of the percent AcH-positive cells (16). To increase transparency, we report histone
368 acetylation changes both as the proportion of AcH-positive cells and by MFI; the 3-4-fold MFI
369 increases we report with RMD and PNB are consistent with prior literature. LRA boosting

370 correlated with increased histone H3 acetylation in CD4⁺ T cells but AZD-associated boosting
371 did not recruit additional CD4s with acetylated histone H3. HDACi monotherapy also did not
372 increase the proportions of acetylated histone H3-positive CD4s and the amount of acetylated
373 histone H3 per cell did not meaningfully correlate with the induction of HIV-1 transcription. It
374 remains unclear if histone acetylation is correlative or causative to virus reactivation. In the
375 context of cellular genes, histone acetylation is not an immediate driver of the transcriptional
376 changes observed with HDACi (73). Similar magnitudes of HIV-1 reactivation were observed
377 with low-dose bryostatin and AZD5582-mediated HDACi boosting and could share common
378 mechanisms. Bryostatin and AZD5582 can activate canonical and non-canonical NF-κB
379 pathways, respectively, and the overlap in signaling with LRA boosting requires further
380 definition. A recent study performed an AZD5582-stimulated CRISPR screen and identified
381 HDAC2 as a potential synergistic drug target (32).

382 We identify that HIV-1 latency during treated virologically suppressed infection in PWH
383 is best described a period of inefficient, but not absent, virus mRNA production in blood. Real-
384 time PCR assays that quantify HIV-1 persistence markers are not necessarily standardized across
385 research groups; the fold-change in HIV-1 unspliced caRNA levels that we observed with PMA-
386 ionomycin stimulation were an order of magnitude lower than some prior studies which
387 quantified polyadenylated HIV-1 mRNA (28, 32). Our findings suggest this is not a result of
388 assay technical performance. Rather, qPCR assays of HIV-1 unspliced and poly(A) caRNA
389 levels may capture distinct biology, as a function of CD4⁺ T cell phenotype. First, we identified
390 tCD4 contain more polyadenylated HIV-1 message than rCD4 in PWH. Second, PMAi
391 stimulation has more pronounced effects on the induction of HIV-1 poly(A) mRNA levels,
392 relative to unspliced RNA, and explains the discrepancy in PMAi-induced HIV-1 caRNA fold-

393 changes between our study and others. Third, PMAi stimulation increases the levels of both
394 HIV-1 unspliced and poly(A) and, in doing so, normalizes their ratios; this normalization is
395 greater in tCD4. Lastly, we identify that during treated virologically suppressed infection, HIV-1
396 transcription generates unspliced transcripts of at least 350 nucleotides in length. We note this is
397 distal to where RNA polymerase II promoter-proximal pausing typically occurs (74). The
398 efficiency of HIV-1 transcription is therefore reduced during ART, but not extinguished. We
399 speculate that while the HIV-1 long terminal repeat (LTR) can recruit RNA polymerase II under
400 these circumstances, the transcription elongation complex may be missing virus and/or host
401 factors required to maximize virus mRNA production and processing.

402 LRA boosting, and their individual components, can have off-target effects. We used cell
403 surface and intracellular assessments of immune activation to investigate whether LRA boosting
404 can be uncoupled from immune activation. Whereas CD69 surface expression has been proposed
405 as a biomarker of latency reversal potency in the context of PKC agonists, we found no
406 correlation between CD69 upregulation and the magnitude of latency reversal (75, 76). We
407 identified less induction of CD69 expression with RMD monotherapy than a prior study, despite
408 similar staining and gating strategies (77). While low-dose bryostatin was sufficient to increase
409 surface activation-induced markers and increase cytokine production in CD4⁺ and CD8⁺ T cells,
410 albeit to relatively low levels, the increased HIV-1 reactivation seen with LRA boosting did not
411 increase surface AIM and in some cases reduced it – specifically by adding an HDACi to
412 bryostatin. However, intracellular cytokine production increased modestly with these same
413 combinations and suggests that AIM assays and ICS staining provide complementary
414 information in the assessment of investigational LRA. Our findings suggest that future
415 investigations into LRA-induced cytokine production should include TNF- α quantifications,

416 whose levels are more likely to increase than either of the more commonly assessed IL-2 and
417 IFN- γ . In contrast, LRA boosting with AZD5582 resulted in relatively lower surface levels of
418 CD69 and no induction of surface activation markers or cytokine production in T cells. Our
419 results extend previous findings on the effects of combination LRA on CD8⁺ T lymphocytes to
420 CD4⁺ T cells (78) and suggest that cytokine assessments of IL-2 production in CD4⁺ T cells
421 provide the least yield in LRA evaluations. We conclude that LRA boosting approaches can
422 affect the immune system differently and may work through different mechanisms. An LRA
423 boosting approach that minimizes immune modulatory effects may be more appealing as an
424 investigational intervention.

425 The variance in HIV-1 LRA responsiveness we document, across participants and
426 between replicates, has implications for future studies. Small studies may be limited in their
427 capacity to accurately quantify this variability, which increases with LRA potency and has been
428 observed in other in vitro and ex vivo work (79-81). We speculate this variability may relate to
429 heterogeneity in the HIV-1 reservoir, less so in the absolute amounts of provirus that may be
430 found in a given PBMC aliquot and more so to the capacity of a given set of proviruses, in their
431 unique intracellular environments, to support the reactivation of virus transcription. Assessments
432 of LRA activity should prioritize larger sample sizes and more than one biological replicate per
433 participant. We found that normalization of HIV-1 transcription to host gene transcription may
434 introduce additional variability. Despite HIV-1 re-activation that was superior to PMA-
435 ionomycin, multiply spliced HIV-1 transcription and virion production did not significantly
436 increase with RMD in combination with low-dose bryostatin. Blocks to HIV-1 splicing are
437 increasingly recognized, and here we extend those findings to novel LRA boosting combinations
438 (23-25, 82-84). PMAi did not induce supernatant viremia, after a 24-hour incubation, in all

439 participants; this heterogeneity has been previously reported (85). In CD4⁺ T cell samples from a
440 subset of participants, however, we did observe detectable supernatant viremia but not increases
441 in the frequency of HIV-1 mRNA with the LRA boosting combination of romidepsin and low-
442 dose bryostatin. It is possible that if an RNA splicing block limits LRA boosting-associated
443 virion production, it may not be absolute. Our study did not evaluate alternative possibilities that
444 virion production without significant HIV-1 mRNA increases may be due to virion production
445 kinetics, i.e. mRNA may be translated and degraded, may be due to the variance in LRA
446 response we document across experimental replicates, or may be due to assay technical
447 differences. Future work should focus on the post-transcriptional mechanisms of HIV-1 RNA
448 processing, and inter-patient differences in LRA responsiveness.

449 To standardize language, the term HIV-1 “latency reversal” may require more precise
450 wording. Latency reversal can refer to the reactivation of virus unspliced or poly(A) mRNA
451 transcription but can also be interpreted to mean the reversal of latency that results in viral
452 particle production. While some prior studies have identified HDACi-induced HIV-1 virion
453 production *ex vivo*, this required HDACi exposures over 6-14 days, at times in combination with
454 CD8 depletion or other LRA conditions that are more difficult to translate into investigational
455 strategies (70, 77, 79, 86).

456 Our study has limitations. Prior and current injection opioid use limits the peripheral
457 blood draw volumes we could obtain; this required us to prioritize the experiments we performed
458 with a given sample. The statistical significance of LRA boosting with AZD5582-containing
459 regimens was not replicated in our HEAL cohort samples and it is unclear if this relates to the
460 variability in LRA response as sample size decreases or to unrecognized differences between our
461 cohort’s participants. We observed variance across clinical cohorts in the magnitude of LRA

462 boosting responses to AZD5582 in combination with HDACi. While the sample sizes for these
463 experiments differ (n=36 vs n=9) and, in aggregate, the HIV-1 caRNA fold-change effects are
464 clear, we cannot rule out that smaller sample sizes and/or unrecognized differences between our
465 cohort's participants may impact the significance and the magnitude of latency reversal with
466 some LRA boosting combinations. Additional mechanisms may explain how LRA boosting
467 increases virus transcription; bryostatin may exert its HIV-1 latency reversal effects
468 independently of PKC agonism (87).

469 The use of HIV-1 LRA at sub-maximal doses and in combination with small molecules
470 that do not increase virus transcription, *ex vivo*, expands our understanding of how virus latency
471 may be reversed. Follow-on studies should delineate the precise mechanisms required for
472 efficient virus RNA processing and virion production during HIV-1 latency reversal.

473

474

475

476

477

478

479

480

481

482

483

484

485 **Figure Legends**

486

487 **Figure 1.** HIV-1 reservoir size and intactness during opioid use. Quantifications were performed
488 on participants who used (n=24) or did not use (n=12) opioids. (a) HIV-1 persistence measures
489 in participants with (blue circles) and without (yellow circles) opioid use are shown. Statistical
490 significance was assessed with Wilcoxon signed-rank tests. Data are displayed on a logarithmic
491 y-axis scale; DNA and RNA was extracted from 5 million PBMC. Intact DNA was quantified
492 with the IPDA assay. Mean values \pm standard errors of the mean (SEM) are shown. (b) 5' and 3'
493 genomic deletions as a function of opioid use, mean values \pm 95% CIs are displayed, (c) Opioid
494 subgroup analysis. The reservoir size of intact, 5' deleted, and 3' deleted or hypermutated
495 regions are shown. (d) The proportion of intact genomes as a function of DNA copies and opioid
496 use subgroup; Kruskal-Wallis testing adjusting for multiple comparisons was not significant.
497 Cohort 1, injection opioid use; cohort 2, prescribed oral opioids for pain; cohort 3, methadone;
498 cohort 4, suboxone; cohort 5, no opioid use.

499

500 **Figure 2.** HIV-1 latency reversal in OPHION participants. HIV-1 caRNA levels were quantified
501 after 24-hour incubations, in the presence of tenofovir 2 μ M and raltegravir 2 μ M, using 5
502 million PBMC and compared to a no-drug DMSO-containing condition. Mean values and the
503 95% CIs are shown. (a) Combined data showing LRA responses in thirty-six total participants
504 with (blue circles) or without (yellow circles) opioid use. Data from (a) was dichotomized by (b)
505 opioid use, (c) sex (light purple circles, male; light grey circles, female), and (d) race (light green
506 circles, Black and American Indian; dark green circles, white). Means and SEM are shown.
507 Dotted horizontal line denotes a fold-change of 1. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and ****

508 p<0.0001 for LRA combinations, corrected for multiple comparisons. α CD3/ α CD28, anti-CD3
509 anti-CD28 superparamagnetic beads; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P,
510 PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM.

511
512 **Figure 3.** Immune activation and cytokine induction during *ex vivo* LRA boosting. (a) Example
513 plots of OX40⁺PD-L1⁺, OX40⁺CD25⁺, and CD69⁺CD40L⁺ expression from gated live CD4⁺ T
514 cells in PBMC samples incubated with DMSO control or an α CD3/ α CD28 bead positive control
515 for 18 hours, (b) Violin plots of surface activation-induced marker (AIM) response as a function
516 of LRA. Results across three highly sensitive AIM assays for OPHION participants' samples
517 (n=36) are shown for comparison, (c) Quantification of LRA-induced surface CD69 expression
518 in live total CD4⁺ T cells (n=36). Intracellular production of the cytokines TNF- α , IFN- γ , and IL-
519 2 during LRA exposure in (d) live CD4⁺ and (e) CD8⁺ T cells (n=36). Violin plot median values
520 are indicated by a solid black line; quartiles are shown with a dotted line. LRA conditions
521 without visible bars represent values < 0.1% of cells. *p<0.05, *** p<0.001, and **** p<0.0001
522 for LRA combinations, corrected for multiple comparisons. RMD, romidepsin; PNB,
523 panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM.

524
525 **Figure 4.** LRA boosting increases histone acetylation. (a) Violin plots showing the proportion of
526 gated live total CD4⁺ T cells with acetylated histone H3, assessed by flow cytometry, (b) Violin
527 plot of mean fluorescence intensity (MFI) of acetylated histone H3 per live CD4⁺ T cell. Scatter
528 plots of acetylated histone H3 levels per CD4 as a function of HIV-1 transcription in response to
529 RMD and PNB monotherapy (c), LRA boosting with HDACi and AZD5582 (d), and HDACi in
530 combination with low-dose bryostatin (e) are shown. Acetylated histone levels and HIV-1

531 reactivation with the combinations of HDACi and bryostatin were moderately positively
532 correlated ($r=.25$, $p=.04$). Violin plot median values are indicated by a solid black line; quartiles
533 are shown with a dotted line.

534

535 **Figure 5.** Comparative analysis of LRA boosting effects in PBMC and CD4⁺ T cells.

536 Leukapheresis samples from HEAL cohort participants ($n=11$) were used to assess HIV-1
537 unspliced caRNA levels during (a) low-dose bryostatin-based and (b) AZD5582-based LRA
538 boosting combinations in PBMC, when compared to PMA-ionomycin. Data are presented as
539 means \pm SEM. Circle color is used to denote a given HEAL participant across Figure panels. (c)
540 Absolute HIV-1 unspliced caRNA levels in parallel PBMC and CD4⁺ T cell LRA exposures.
541 PBMC and CD4 results are separated by a vertical dotted line. (d) Representation of the data in
542 (c) as fold-change in HIV-1 caRNA levels. (e) Corresponding HIV-1 RNA levels from culture
543 supernatants. (f) Multiply spliced HIV-1 RNA levels as determined in a modified TILDA assay,
544 comparing RMD-bryostatin combinations at two bryostatin concentrations to PMA-ionomycin.
545 (g) Combined OPHION and HEAL participant results ($n=47$) that summarize PBMC LRA
546 boosting responses, for LRA conditions common to both datasets. Results from OPHION
547 participant samples, carried over from Fig. 2a, are shown in grey circles. HEAL participant
548 results are shown in color. * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$, corrected for
549 multiple comparisons. NDC, no-drug control, contains 0.2% DMSO; PMAi, PMA with
550 ionomycin; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin
551 1nM; A, AZD5582 100nM.

552

553 **Figure 6.** Latency reversal polyadenylates pre-existing unspliced HIV-1 mRNA (a) Resting and
554 total CD4⁺ T cell HIV-1 transcriptional profiles during PMA-ionomycin exposure. HEAL
555 participant samples (n=10) were used to assess the effects of CD4⁺ T cell phenotype and cell
556 culture density on fold-changes in HIV-1 unspliced and poly(A) transcripts during latency
557 reversal with PMA-ionomycin. (b) Ratios of HIV-1 unspliced and poly(A) transcripts in resting
558 and total CD4⁺ T cells isolated from PWH. The effects of PMA-ionomycin and cell density on
559 HIV-1 latency reversal in (c) resting CD4⁺ T cells, (d) total CD4⁺ T cells, and (e) the specific
560 ratios of HIV-1 caRNA production in rCD4 compared to tCD4 when plated at a density of 1
561 million cells/mL, are shown. A given HEAL participant is indicated by circle color. Ratios of
562 HIV-1 caRNA are the ratios of unspliced HIV-1 caRNA to poly(A) HIV-1 mRNA. *p<0.05, **
563 p<0.01, corrected for multiple comparisons in panels a-d. Panel e was assessed with a Wilcoxon
564 matched-pairs signed rank test. rCD4, resting (CD25-CD69-HLA-DR-) CD4⁺ T cells; tCD4,
565 total CD4⁺ T cells; NDC, no drug control condition; PMA, PMA 50ng/mL with ionomycin 1µM;
566 Poly-A, polyadenylated HIV-1 caRNA; unspliced, HIV-1 unspliced caRNA; 1m, 1million
567 cells/mL culture media; 5m, 5 million cells/mL culture media.

568

569

570

571

572

573

574

575

576

577 **Materials and Methods**

578 **Study Design and Clinical Cohorts**

579 The Opioids, HIV, and Translation (OPHION) study is a prospective cohort study of participants
580 living with HIV on suppressive antiretroviral therapy recruited from Boston Medical Center
581 which serves one of the largest populations of people living with HIV (PLWH) in Massachusetts,
582 including a disproportionately large number of persons with opioid and substance use disorders.
583 Eligible PLWH were required to currently be on antiretroviral therapy and virologically
584 suppressed (defined as undetectable plasma HIV-1 RNA or <20 copies/ml) for a minimum of 12
585 months prior to enrollment. Individuals were recruited into 1 of 5 cohorts: (1) active injection
586 opioid use, defined as self-report on injecting opioids at least once per week, (2) Methadone
587 maintenance therapy for at least 3 months, (3) buprenorphine-naloxone therapy for at least 3
588 months, (4) Prescription oral opioid use for at least 6 months or (5) No opioid use within the past
589 1 year representing a control cohort. Eligibility into each of the five cohorts was confirmed with
590 a urine toxicology performed at the BMC central laboratory, which includes evaluation for urine
591 drug metabolites including opiates and non-opioid substances as well as an expanded opioid
592 panel which included fentanyl or norfentanyl metabolites. Exclusionary criteria included ongoing
593 immunosuppression and pregnancy; patients who reported injecting non-opioid substances were
594 also not eligible. Once consented and enrolled, each participant underwent blood collection for
595 same day PBMC extraction as well as urine collection for gabapentin and benzodiazepine
596 metabolites. Participants also completed an extensive survey on their current and prior substance
597 use (including alcohol and tobacco use) based the addiction severity index (ASI) (88) and Texas
598 Christian University (TCU) drug screen (89). HIV and other clinical information including ART

599 treatment history, duration of virologic suppression and comorbidity status including hepatitis C
600 and B were abstracted from the medical record.

601 The HIV Eradication and Latency (HEAL) Cohort is a longitudinal biorepository study of
602 participants with HIV. Inclusion criteria for HEAL participants in this study were 1)
603 antiretroviral therapy-treated participants with HIV-1 who were virologically suppressed, defined
604 as plasma HIV-1 RNA less than assay (most commonly less than 20 copies/mL, without blips)
605 for >1 year and 2) had sufficient available amounts of cryopreserved PBMC for the proposed
606 analyses. These cohort studies are performed in accordance with the principles of the Declaration
607 of Helsinki. The institutional review boards at Boston Medical Center and Brigham and
608 Women's Hospital (Mass General Brigham Human Research Committee) approved the study
609 protocols. Written informed consent was obtained from all participants. Experimenters were
610 blinded to all clinical data and to OPHION subgroup assignments.

611

612 **Quantification of HIV-1 persistence markers**

613 Genomic DNA and total RNA were isolated from approximately 5×10^6 peripheral blood
614 mononuclear cells (PBMC) or total CD4⁺ T cells (AllPrep DNA/RNA kit, Qiagen). Total HIV-1
615 DNA and unspliced cell-associated RNA (caRNA) levels were quantified in triplicate by real-
616 time PCR as previously described, modified to include Taqman Universal Mastermix (DNA) or
617 Taqman Fast Virus 1-Step Mastermix (RNA) (90). HIV-1 quantifications used forward primer
618 5'-TACTGACGCTCTCGCACC-3', reverse primer 5'-TCTCGACGCAGGACTCG-3', and
619 probe 5' FAM-CTCTCTCCTTCTAGCCTC-MGB 3' (ThermoFisher Scientific). DNA cycling
620 conditions in a total reaction volume of 25 μ L were 95°C for 15 min followed by 40 cycles of
621 95°C for 15 sec and 60°C for 1 min. RNA cycling conditions in a total reaction volume of 20 μ L

622 were 55°C for 15 min, 95°C for 20 sec, followed by 40 cycles of 95°C for 3 sec and 60°C for 30
623 sec. Approximately 500ng of genomic DNA were assessed per well. The limits of quantification
624 for total HIV-1 DNA and unspliced caRNA were 1 and 3 copies per reaction, respectively.
625 Limits of detection were calculated per timepoint and participant sample, considering the
626 average number of copies detected across triplicate measurements. Cell input numbers were
627 quantified by human genome equivalents of CCR5 DNA using forward primer 5'-
628 ATGATTCCTGGGAGAGACGC-3', reverse primer 5'-AGCCAGGACGGTCACCTT-3', and
629 probe 5' FAM-CTCTCTCCTTCTAGCCTC-MGB 3' (ThermoFisher Scientific) as described
630 (90).

631

632 **Intact proviral DNA assay**

633 HIV-1 DNA from isolated PBMC DNA was measured using the intact proviral DNA assay
634 (IPDA) as previously described with minor modifications (91). Two multiplexed droplet digital
635 PCR assays (Bio-Rad QX200) were performed per sample targeting conserved HIV-1 sequences
636 and, to normalize data, a cell reference gene. Master mixes were prepared using 2X ddPCR
637 Supermix for probes. The HIV-1 specific reaction targeted the *Psi* packaging signal (Forward 5'-
638 CAGGACTCGGCTTGCTGAAG-3'; Reverse 5'-GCACCCATCTCTCTCCTTCTAGC-3';
639 Probe 5'-TTTTGGCGTACTCACCAGT-3', FAM, MGB) and *env* (Forward: 5'-
640 AGTGGTGCAGAGAGAAAAAAGAGC-3'; Reverse: 5'-GTCTGGCCTGTACCGTCAGC-3';
641 Probe intact: 5'-CCTTGGGTTCTTGGGA-3', VIC/HEX, MGB) sequences with 700 ng DNA
642 per well in duplicate. An additional probe without a fluorophore targeting hypermutated *env*
643 sequence (Probe hypermutated: 5'-CCTTAGGTTCTTAGGAGC-3', Unlabeled, MGB) was used
644 to exclude defective gene quantification. To estimate the number of cells per reaction and correct

645 for sheared DNA, separate reactions targeting two regions of the *RPP30* gene, RPP30-1
646 (Forward: 5'-GATTTGGACCTGCGAGCG-3'; Reverse: 5'-GCGGCTGTCTCCACAAGT-3';
647 Probe: 5'-CTGACCTGAAGGCTCT-3', VIC/HEX, MGB) and RPP30-2 (Forward: 5'-
648 GACACAATGTTTGGTACATGGTTAA-3'; Reverse: 5'-
649 CTTTGCTTTGTATGTTGGCAGAAA-3'; Probe: 5'-
650 CCATCTCACCAATCATTCTCCTTCCTTC -3', VIC/HEX), with similar nucleotide distance
651 between targets compared to *Psi* and *env* were prepared with 70 ng DNA per well. Droplets were
652 generated and subjected to PCR cycle: 95°C for 10 minutes, followed by 45 cycles of 94°C for
653 30 seconds, 59°C for 1 minute, and ending with 98°C for 10 minutes before holding at 4°C. Data
654 from PCR products were collected and analyzed using QuantaSoft Data Analysis Software.
655 Droplets containing a double positive signal (*Psi+/env+*) were considered intact, while single
656 positive droplets represented defective provirus containing 5' deletions (*Psi-/env+*) or 3'
657 deletions/hypermutations (*Psi+/env-*). Relative DNA shearing was calculated using the ratio of
658 single positive RPP30 droplets compared to the double positive population and was used to
659 estimate the number of intact proviruses. The number of diploid cells in each reaction was
660 determined by dividing the copies of RPP30 in half and correcting for the dilution factor for the
661 HIV-1 reaction. Intact, defective, and total HIV-1 DNA were normalized to the number of cells
662 and reported as copies/million PBMC.

663

664 **Multiply spliced HIV-1 transcripts**

665 To measure the frequency of total CD4⁺ T cells with inducible multiply spliced HIV-1 RNA, we
666 performed the TILDA assay, as previously described, with two modifications (56). First, to
667 reduce the 95% CIs around our frequency estimates, we used 36 x 10⁶ cells/mL as our first

668 dilution, rather than the 18×10^6 cells/mL used in Procopio, et al. Second, to harmonize our
669 PMA-ionomycin concentrations with LRA experiments, we reduced the PMA concentration
670 from its original 100 ng/mL to 50ng/mL in our TILDA assays. The duration of virologic
671 suppression in our HEAL participants was similar to previously reported participants (56).

672

673 **Reference gene quantification**

674 Extracted PBMC RNA was used to quantify transcription levels of three host genes, IPO8, TBP,
675 and UBE2D2, typically immediately after the loading of HIV-1 caRNA qPCR plates was
676 complete. IPO8 quantifications used forward primer 5' - CCTTTGTACAACAGAAGGCAC -3',
677 reverse primer 5' - TGCACGTCTCAGGTTTTTGC -3', and probe 5' FAM-
678 TCCGCATAAATCCATTGATTCTGC -MGB 3' (ThermoFisher Scientific); TBP
679 quantifications used forward primer 5' - CAGTGAATCTTGGTTGTAACTTGA -3', reverse
680 primer 5' - TCGTGGCTCTCTTATCCTCAT -3', and probe 5' FAM-
681 CGCAGCAAACCGCTTGGGATTAT -MGB 3' (ThermoFisher Scientific); and UBE2D2
682 quantifications used forward primer 5' - GTECTCTTGCCATCTGTTCTCTG -3', reverse
683 primer 5' - CCATTCCCGAGCTATTCTGTT -3', and probe 5' VIC-
684 CCGAGCAATCTCAGGCACTAAAGGA -MGB 3' (ThermoFisher Scientific). To generate
685 IPO8 standards, we cloned a fragment corresponding to nucleotides 3636-3707 of IPO8 mRNA
686 (Sequence ID NM_006390.4) into a pCR4-TOPO vector (ThermoFisher Scientific, Cat. No.
687 K458001). To generate TBP standards, a fragment corresponding to nucleotides 649-1037 of
688 TBP mRNA (Sequence ID NM_003194) was cloned into a pCR4-TOPO vector. To generate
689 UBE2D2 standards, a fragment corresponding to nucleotides 729-1164 of UBE2D2 mRNA
690 (Sequence ID NM_181838.2) was cloned into a pCR4-TOPO vector. Reference gene RNA was

691 synthesized using T3 Megascript Kit (ThermoFisher Cat. No. AM1333 and cleaned (RNease
692 MinElute Cleanup Kit, Qiagen, Cat. No. 74204) before serially diluting across a range of 10^6 –
693 10^3 copies per well. After TBP and UBE2D2 standards were individually validated, TBP (T)
694 and UBE2D2 (U) RNA were diluted separately and aliquoted together as one set of multiplex
695 standards. T and U standards were validated to demonstrate overlap of individual and
696 multiplexed standards curves. The assay was optimized to run all host gene standards and
697 samples on one 96-well reaction plate in a total reaction volume of 20 μ L using cycling
698 conditions of 55°C for 5 min, 95°C for 20 sec, followed by 40 cycles of 95°C for 3 sec and 56°C
699 for 30 sec. Reference gene standards and samples were run in duplicate. IPO8, TBP, and
700 UBE2D2 RNA copies per million PBMC were calculated by dividing copies per total sample by
701 number of cells per sample, determined by CCR5 quantification, and normalized to 1×10^6 cells.
702 Fold changes were calculated by dividing the RNA copy number obtained per million PBMC for
703 each LRA condition by the 0.2% DMSO control condition's reference gene RNA copies/million
704 PBMC.

705

706 **HIV-1 latency reversal**

707 OPHION and HEAL participant peripheral blood mononuclear cells (PBMC) were isolated from
708 large volume (90 – 180cc) peripheral blood or leukapheresis collections by density centrifugation
709 and cryopreserved. Cryopreserved PBMC were thawed, pelleted, and transferred to RPMI media
710 supplemented with 10% fetal bovine serum, 2 μ M raltegravir, and 2 μ M tenofovir (R10 +
711 TDF/RAL) at a concentration of 1×10^6 cells/mL. Cells were rested in a humidified CO₂
712 incubator at 37°C for three hours (hrs). After 3hrs, cells were counted and assessed for viability.
713 For CD4⁺ T cell experiments, PBMC were pelleted, resuspended in EasySep Buffer (StemCell

714 Technologies, cat. no. 20144), and isolated with EasySep Human CD4⁺ T Cell Enrichment Kit
715 (StemCell cat. no. 19052) per the manufacturer's instructions. A total of 5×10^6 PBMC, or total
716 CD4⁺ T cells, were aliquoted into 5mL of fresh R10 + RAL/TDF in 6-well sterile cell culture
717 plates. Cells were incubated in the presence or absence of the following LRA conditions: 0.2%
718 DMSO, 1:1 α CD3/ α CD28 beads (Life Technologies, cat. no. 11131D) to cells with 30 U/mL IL-
719 2 (R&D Systems, cat. no. 202-IL-500), romidepsin 20 nM (Sigma, cat. no. SML1175),
720 panobinostat 30nM (Sigma, cat. no. SML3060), bryostatin-1 1nM (Sigma, cat. no. B7431),
721 AZD5582 100nM (ChemieTek, cat. no. CT-A5582), romidepsin 20 nM plus bryostatin-1 1nM,
722 panobinostat 30nM plus bryostatin-1 1nM 100nM, romidepsin 20 nM plus AZD5582 100nM,
723 panobinostat 30nM plus AZD5582 100nM, and phorbol 12-myristate 13-acetate (PMA)
724 50ng/mL (Sigma, cat. no. P1585) in combination with ionomycin 1 μ M (Sigma, cat. no. I9657).
725 To provide a known positive control for subsequent immunology assessments, α CD3/ α CD28
726 beads were used with OPHION samples. Cultures were incubated at 37°C for 24 hours. After 24
727 hours, cells were prepared for nucleic acid extractions.

728

729 **Comparison of qPCR assays after reactivation**

730 CD4⁺ T cells were isolated from cryopreserved HEAL participant PBMCs. Total CD4s (tCD4)
731 were isolated using a CD3+CD4+CD8- isolation kit (StemCell cat. no. 17952) and resting CD4s
732 (rCD4) were isolated using a CD3+CD4+CD8-CD25-CD69-HLA-DR- isolation kit (StemCell
733 cat. no. 17962). Cells were pelleted and transferred to RPMI media supplemented with 10% fetal
734 bovine serum, 2 μ M raltegravir, and 2 μ M tenofovir (R10 + TDF/RAL) at a concentration of
735 5×10^6 cells/mL. Cells were rested in a humidified CO₂ incubator at 37°C for 3h and then counted
736 and assessed for viability. A total of 5×10^6 tCD4s or rCD4⁺ T cells were aliquoted into either

737 1mL or 5mL of fresh R10 + RAL/TDF in a 24-well sterile cell culture plate or 6-well sterile cell
738 culture plate, respectively. Cells were incubated in either 0.2% DMSO or phorbol 12-myristate
739 13-acetate (PMA) 50ng/mL (Sigma, cat. no. P1585) in combination with ionomycin 1µM
740 (Sigma, cat. no. I9657). Cultures were incubated at 37°C for 24 hours. After 24 hours, cells were
741 prepared for nucleic acid extractions. RNA was eluted in a total volume of 65uL and DNA eluted
742 in a volume of 100uL. For HIV-1 unspliced caRNA quantifications, 10uL of RNA were assessed
743 in triplicate using primers and probe that bind the HIV-1 *gag* region (90). To calculate copies of
744 HIV-1 caRNA per million cells, copy numbers were averaged and cell counts normalized to a
745 CCR5 DNA reference. For polyadenylated HIV-1 mRNA quantifications, 10uL (approximately
746 1 million cell equivalents) of RNA were run in triplicate using primers and probe targeting the
747 nef to poly-A region of HIV-1 mRNA as previously described (28). Our HIV-1 unspliced and
748 poly(A) caRNA amplifications are both one-step qPCR assays that use an HIV-specific primer to
749 synthesize cDNA. Standards were generated as previously described (92). For poly(A) HIV-1
750 mRNA quantifications, copies per million cell equivalents were calculated by initial cell count
751 prior to reactivation. Both assays used Taqman Fast Virus 1-Step Mastermix in a total reaction
752 volume of 20µL and cycling conditions of 55°C for 15 min, 95°C for 20 sec, followed by 40
753 cycles of 95°C for 3 sec and 60°C for 30 sec. Fold-change was calculated by dividing copies per
754 million cells in the PMAi condition by copies per million cells in the 0.2% DMSO no drug
755 control condition for each sample.

756

757 **Activation Induced Marker (AIM) assay**

758 AIM assays were performed as previously described (54). Briefly, cryopreserved PBMC were
759 thawed, washed, resuspended in R10, and rested for 3 hours at 37°C. Following the 3-hour rest

760 interval, the appropriate number of cells were transferred to a 48-well plate and subsequently
761 treated with CD40 blocking antibody (Miltenyi Biotec, cat. no. 130-094-133) for a final
762 concentration of 0.5ug/mL for 15 minutes at 37°C. Cells were incubated in the presence or
763 absence of our 10-LRA panel, as previously described. After an 18hr incubation, cells were
764 harvested and stained for 50 minutes at 4°C with the surface staining monoclonal antibodies
765 (mAb); (PD-L1-PE/Cy7 (Biolegend, cat. no. 329717), CD40L-PE (BD Biosciences [BD], cat.
766 no. 561720), OX40-APC (BD cat. no. 563473), CD69-BV650 (Biolegend cat. no. 310933),
767 CD3-BV605 (Biolegend cat. no. 317322), CD4-BV421 (BD cat. no. 562424), CD8-PerCp-Cy5.5
768 (BD cat. no. 560662), CD25- BUV395 (BD cat. no. 564034) and LIVE/DEAD Near-IR stain
769 (ThermoFisher cat. no. L34975), washed, fixed and permeabilized (BD cytofix fixation buffer,
770 cat. no. 554655), and then stained for 30 minutes at 4°C with intracellular mAb Acetyl-histone
771 H3-Alexa Fluor 488 (Cell Signaling Technology, cat. no. 9683S) in 1x perm/wash buffer (BD,
772 cat. no. 554723). The cells were washed and fixed (BD cytofix fixation buffer, cat. no. 554655)
773 prior to flow cytometry analysis.

774

775 **Intracellular cytokine staining**

776 Cryopreserved PBMC were thawed, washed, resuspended in RPMI + 10% FBS (R10), and
777 rested for 3 hours at 37°C. Following the 3-hour rest interval, the appropriate number of cells
778 were transferred to a 48-well plate and incubated for 2 hrs with our panel of 10 LRA. Following
779 this 2-hour incubation period, GolgiPlug (BD, cat. no. 555029) and GolgiStop (BD, cat. no.
780 554724) were added to each condition at a concentration of 1:1000 and 6:10000 respectively,
781 then incubated at 37°C for an additional 16 hrs. Cells were harvested, pelleted, resuspended,
782 stained for 20 minutes at 4°C with surface staining mAb (CD3-BV605, CD4-BV421, CD8-

783 PerCp-Cy5.5 and LIVE/DEAD Near-IR stain), fixed and permeabilized as described above, and
784 then stained for 30 minutes at 4°C with the intracellular mAb TNF- α - PE/Dazzle-594 (Biolegend
785 cat. no. 502946), IL-2- PE/Cy7 (BD cat. no. 560707) and IFN- γ - BV510 (Biolegend cat. no.
786 502544). PBMC were washed and fixed in (BD cytofix fixation buffer, cat. no. 554655) prior to
787 flow cytometry analysis, as described above.

788

789 **Flow cytometry**

790 Cells were acquired on a BD LSRFortessa using FACSDiva. Analysis was performed using
791 FlowJo software versions 10.6.2 (Treestar, Versions 10 for Mac). Representative gating
792 strategies can be found in the supplemental figures.

793

794 **Statistical analysis**

795 Statistical analyses were performed using GraphPad Prism 9 for macOS. Means, medians, 95%
796 confidence intervals, and standard errors of the mean were calculated. The pre-specified primary
797 outcome of OPHION was a comparison of log₁₀ PBMC HIV-1 caRNA levels between
798 participants who use and do not use opioids. The pre-specified outcome for OPHION latency
799 reversal experiments was the difference in HIV-1 caRNA levels between LRA treatment groups
800 and across opioid use groups. To assess for changes in HIV-1 caRNA, we performed Kruskal-
801 Wallis testing of all participants together for each of the LRAs with Dunn's multiple comparison
802 test, comparing the mean ranks of LRA conditions. An identical approach was taken with a
803 series of exploratory analyses with OPHION participant samples that assessed histone
804 acetylation, surface activation, and intracellular cytokine production, and with the exploratory

805 statistical analyses performed on experiments with HEAL participant samples, unless otherwise
806 specifically stated in the text.

807

808 **Acknowledgements**

809 This work is supported by the National Institutes of Health (NIH) R61 DA047038 (NL and AT)
810 and R33 DA047038 (AT) and was facilitated by the Providence/Boston Center for AIDS
811 Research (P30AI042853) and the Harvard University Center for AIDS Research (P30AI060354).
812 The project described was further supported by Clinical Translational Science Award
813 1UL1TR002541-01 to Harvard University and Brigham and Women's Hospital from the
814 National Center for Research Resources. The content is solely the responsibility of the authors
815 and does not necessarily represent the official views of the National Center for Research
816 Resources or the National Institutes of Health.

817

818 **Author contributions:**

819 Conceptualization: AA, JT, KC, NL, AT

820 Methodology: AA, JT, KC, NL, AT

821 Investigation: TL, JB, AA, AO, KC, HC, HJ, KC

822 Visualization: TL, JB, AA, AO, KC, AT

823 Funding acquisition: NL, AT

824 Project administration: AA, SR, NL, AT

825 Supervision: AA, NL, AT

826 Writing – original draft: TL, JB, AA, AO, NL, AT

827 Writing – review & editing: TL, AA, NL, AT

828

829 **Declaration of interests:** NL is now an employee of Moderna, Inc. AT has received
830 remuneration from EBSCO Dynamed. Additional authors declare that they have no competing
831 interests.

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851 **References**

- 852 1. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a
853 pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proceedings of
854 the National Academy of Sciences of the United States of America. 1998;95(15):8869-73.
- 855 2. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid
856 seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature.
857 2014;512(7512):74-7.
- 858 3. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery
859 of replication-competent HIV despite prolonged suppression of plasma viremia. Science (New
860 York, NY. 1997;278(5341):1291-5.
- 861 4. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an
862 inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the
863 National Academy of Sciences of the United States of America. 1997;94(24):13193-7.
- 864 5. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent
865 infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in
866 patients on effective combination therapy. Nature medicine. 1999;5(5):512-7.
- 867 6. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term
868 follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.
869 Nature medicine. 2003;9(6):727-8.
- 870 7. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV
871 reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature
872 medicine. 2009;15(8):893-900.

- 873 8. Mullins JI, Frenkel LM. Clonal Expansion of Human Immunodeficiency Virus-Infected
874 Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy. The
875 Journal of infectious diseases. 2017;215(suppl_3):S119-S27.
- 876 9. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, et al.
877 International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature
878 medicine. 2016.
- 879 10. Ferrari G, Pollara J, Tomaras GD, Haynes BF. Humoral and Innate Antiviral Immunity as
880 Tools to Clear Persistent HIV Infection. The Journal of infectious diseases.
881 2017;215(suppl_3):S152-S9.
- 882 11. Riley JL, Montaner LJ. Cell-Mediated Immunity to Target the Persistent Human
883 Immunodeficiency Virus Reservoir. The Journal of infectious diseases. 2017;215(suppl_3):S160-
884 S71.
- 885 12. McMahon DK, Zheng L, Cyktor JC, Aga E, Macatangay BJ, Godfrey C, et al. A Phase
886 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on
887 Suppressive Antiretroviral Therapy. The Journal of infectious diseases. 2021;224(4):648-56.
- 888 13. Scully EP, Aga E, Tsibris A, Archin N, Starr K, Ma Q, et al. Impact of Tamoxifen on
889 Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral
890 Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clin Infect Dis.
891 2022;75(8):1389-96.
- 892 14. Gutierrez C, Serrano-Villar S, Madrid-Elena N, Perez-Elias MJ, Martin ME, Barbas C, et
893 al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.
894 AIDS (London, England). 2016;30(9):1385-92.

- 895 15. Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. HIV-1
896 expression within resting CD4+ T cells after multiple doses of vorinostat. *The Journal of*
897 *infectious diseases*. 2014;210(5):728-35.
- 898 16. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al.
899 Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. *Nature*.
900 2012;487(7408):482-5.
- 901 17. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation
902 of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive
903 antiretroviral therapy. *PLoS pathogens*. 2014;10(10):e1004473.
- 904 18. Sogaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, et al. The
905 Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. *PLoS pathogens*.
906 2015;11(9):e1005142.
- 907 19. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al.
908 Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected
909 patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. *The lancet*
910 *HIV*. 2014;1(1):e13-21.
- 911 20. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. Valproic acid
912 in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs:
913 results from a multicentre randomized clinical study. *HIV medicine*. 2012;13(5):291-6.
- 914 21. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, et al.
915 Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. *AIDS*
916 (London, England). 2008;22(10):1125-9.

- 917 22. Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, et al. Interval dosing
918 with the HDAC inhibitor vorinostat effectively reverses HIV latency. *The Journal of clinical*
919 *investigation*. 2017;127(8):3126-35.
- 920 23. Yukl SA, Kaiser P, Kim P, Telwatte S, Joshi SK, Vu M, et al. HIV latency in isolated
921 patient CD4(+) T cells may be due to blocks in HIV transcriptional elongation, completion, and
922 splicing. *Science translational medicine*. 2018;10(430).
- 923 24. Moron-Lopez S, Kim P, Sogaard OS, Tolstrup M, Wong JK, Yukl SA. Characterization
924 of the HIV-1 transcription profile after romidepsin administration in ART-suppressed
925 individuals. *AIDS (London, England)*. 2019;33(3):425-31.
- 926 25. Zerbato JM, Houry G, Zhao W, Gartner MJ, Pascoe RD, Rhodes A, et al. Multiply
927 spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following
928 reversal of HIV latency. *EBioMedicine*. 2021;65:103241.
- 929 26. Martin HA, Kadiyala GN, Telwatte S, Wedrychowski A, Chen TH, Moron-Lopez S, et
930 al. New Assay Reveals Vast Excess of Defective over Intact HIV-1 Transcripts in Antiretroviral
931 Therapy-Suppressed Individuals. *Journal of virology*. 2022;96(24):e0160522.
- 932 27. Rodari A, Darcis G, Van Lint CM. The Current Status of Latency Reversing Agents for
933 HIV-1 Remission. *Annu Rev Virol*. 2021;8(1):491-514.
- 934 28. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, et al. Ex vivo
935 analysis identifies effective HIV-1 latency-reversing drug combinations. *The Journal of clinical*
936 *investigation*. 2015;125(5):1901-12.
- 937 29. Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, et al. BIRC2/cIAP1 Is
938 a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to
939 Promote Reversal of Viral Latency. *Cell host & microbe*. 2015;18(3):345-53.

- 940 30. Grau-Exposito J, Luque-Ballesteros L, Navarro J, Curran A, Burgos J, Ribera E, et al.
941 Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T
942 subpopulations. *PLoS pathogens*. 2019;15(8):e1007991.
- 943 31. Pardons M, Fromentin R, Pagliuzza A, Routy JP, Chomont N. Latency-Reversing Agents
944 Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on
945 Antiretroviral Therapy. *Cell Rep*. 2019;29(9):2783-95 e5.
- 946 32. Dai W, Wu F, McMyn N, Song B, Walker-Sperling VE, Varriale J, et al. Genome-wide
947 CRISPR screens identify combinations of candidate latency reversing agents for targeting the
948 latent HIV-1 reservoir. *Science translational medicine*. 2022;14(667):eabh3351.
- 949 33. Gupta V, Dixit NM. Trade-off between synergy and efficacy in combinations of HIV-1
950 latency-reversing agents. *PLoS computational biology*. 2018;14(2):e1006004.
- 951 34. Kao SY, Calman AF, Luciw PA, Peterlin BM. Anti-termination of transcription within
952 the long terminal repeat of HIV-1 by tat gene product. *Nature*. 1987;330(6147):489-93.
- 953 35. Adams M, Sharmeen L, Kimpton J, Romeo JM, Garcia JV, Peterlin BM, et al. Cellular
954 latency in human immunodeficiency virus-infected individuals with high CD4 levels can be
955 detected by the presence of promoter-proximal transcripts. *Proceedings of the National Academy
956 of Sciences of the United States of America*. 1994;91(9):3862-6.
- 957 36. Lassen KG, Bailey JR, Siliciano RF. Analysis of human immunodeficiency virus type 1
958 transcriptional elongation in resting CD4+ T cells in vivo. *Journal of virology*.
959 2004;78(17):9105-14.
- 960 37. Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, et al.
961 Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of
962 inflammation or activation. *PLoS pathogens*. 2017;13(4):e1006285.

- 963 38. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative
964 analysis of measures of viral reservoirs in HIV-1 eradication studies. *PLoS pathogens*.
965 2013;9(2):e1003174.
- 966 39. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, et al. Cell-based measures of
967 viral persistence are associated with immune activation and programmed cell death protein 1
968 (PD-1)-expressing CD4+ T cells. *The Journal of infectious diseases*. 2013;208(1):50-6.
- 969 40. Telwatte S, Lee S, Somsouk M, Hatano H, Baker C, Kaiser P, et al. Gut and blood differ
970 in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the
971 mechanisms that govern HIV latency. *PLoS pathogens*. 2018;14(11):e1007357.
- 972 41. Edelman EJ, Gordon K, Becker WC, Goulet JL, Skanderson M, Gaither JR, et al. Receipt
973 of opioid analgesics by HIV-infected and uninfected patients. *J Gen Intern Med*. 2013;28(1):82-
974 90.
- 975 42. Reddon H, Milloy MJ, Simo A, Montaner J, Wood E, Kerr T. Methadone maintenance
976 therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit
977 drug users. *AIDS Behav*. 2014;18(4):740-6.
- 978 43. Tavitian-Exley I, Vickerman P, Bastos FI, Boily MC. Influence of different drugs on HIV
979 risk in people who inject: systematic review and meta-analysis. *Addiction*. 2015;110(4):572-84.
- 980 44. Borner C, Kraus J, Bedini A, Schraven B, Hollt V. T-cell receptor/CD28-mediated
981 activation of human T lymphocytes induces expression of functional mu-opioid receptors. *Mol*
982 *Pharmacol*. 2008;74(2):496-504.
- 983 45. Borner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, et al. Mechanisms
984 of opioid-mediated inhibition of human T cell receptor signaling. *J Immunol*. 2009;183(2):882-9.

- 985 46. Mbonye U, Karn J. Transcriptional control of HIV latency: Cellular signaling pathways,
986 epigenetics, happenstance and the hope for a cure. *Virology*. 2014.
- 987 47. Basukala B, Rossi S, Bendiks S, Gnatienco N, Patts G, Krupitsky E, et al. Virally
988 Suppressed People Living with HIV Who Use Opioids Have Diminished Latency Reversal.
989 *Viruses*. 2023;15(2).
- 990 48. Telwatte S, Kim P, Chen TH, Milush JM, Somsouk M, Deeks SG, et al. Mechanistic
991 differences underlying HIV latency in the gut and blood contribute to differential responses to
992 latency-reversing agents. *AIDS (London, England)*. 2020;34(14):2013-24.
- 993 49. Martin AR, Pollack RA, Capoferri A, Ambinder RF, Durand CM, Siliciano RF.
994 Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-
995 associated toxicity. *The Journal of clinical investigation*. 2017;127(2):651-6.
- 996 50. Yang X, Wang Y, Lu P, Shen Y, Zhao X, Zhu Y, et al. PEBP1 suppresses HIV
997 transcription and induces latency by inactivating MAPK/NF-kappaB signaling. *EMBO Rep*.
998 2020;21(11):e49305.
- 999 51. Carlin E, Greer B, Lowman K, Duverger A, Wagner F, Moylan D, et al. Extensive
1000 proteomic and transcriptomic changes quench the TCR/CD3 activation signal of latently HIV-1
1001 infected T cells. *PLoS pathogens*. 2021;17(1):e1008748.
- 1002 52. Palermo E, Acchioni C, Di Carlo D, Zevini A, Muscolini M, Ferrari M, et al. Activation
1003 of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic
1004 Regulators. *Journal of virology*. 2019;93(21).
- 1005 53. Nixon CC, Mavigner M, Sampey GC, Brooks AD, Spagnuolo RA, Irlbeck DM, et al.
1006 Systemic HIV and SIV latency reversal via non-canonical NF-kappaB signalling in vivo. *Nature*.
1007 2020;578(7793):160-5.

- 1008 54. Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, et al. Comparative
1009 analysis of activation induced marker (AIM) assays for sensitive identification of antigen-
1010 specific CD4 T cells. *PLoS ONE*. 2017;12(10):e0186998.
- 1011 55. Ceriani C, Streeter GS, Lemu KJ, James KS, Ghofrani S, Allard B, et al. Defining stable
1012 reference genes in HIV latency reversal experiments. *Journal of virology*. 2021;95(11).
- 1013 56. Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, et al. A Novel
1014 Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.
1015 *EBioMedicine*. 2015;2(8):874-83.
- 1016 57. Mehandru S, Deren S, Kang SY, Banfield A, Garg A, Garmon D, et al. Behavioural,
1017 Mucosal and Systemic Immune Parameters in HIV-infected and Uninfected Injection Drug
1018 Users. *J Addict Res Ther*. 2015;6(4):1-8.
- 1019 58. Deren S, Cleland CM, Lee H, Mehandru S, Markowitz M. Brief Report: The Relationship
1020 Between Injection Drug Use Risk Behaviors and Markers of Immune Activation. *Journal of*
1021 *acquired immune deficiency syndromes (1999)*. 2017;75(1):e8-e12.
- 1022 59. Khoury G, Fromentin R, Solomon A, Hartogensis W, Killian M, Hoh R, et al. Human
1023 Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node
1024 Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive
1025 Antiretroviral Therapy. *The Journal of infectious diseases*. 2017;215(6):911-9.
- 1026 60. Massanella M, Fromentin R, Chomont N. Residual inflammation and viral reservoirs:
1027 alliance against an HIV cure. *Current opinion in HIV and AIDS*. 2016;11(2):234-41.
- 1028 61. Ruggiero A, De Spiegelaere W, Cozzi-Lepri A, Kiselina M, Pollakis G, Beloukas A, et
1029 al. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral

- 1030 Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.
1031 EBioMedicine. 2015;2(9):1153-9.
- 1032 62. Cockerham LR, Siliciano JD, Sinclair E, O'Doherty U, Palmer S, Yukl SA, et al. CD4+
1033 and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. PLoS ONE.
1034 2014;9(10):e110731.
- 1035 63. Kirk GD, Astemborski J, Mehta SH, Ritter KD, Laird GM, Bordi R, et al. Nonstructured
1036 Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir
1037 Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. The Journal of
1038 infectious diseases. 2021;223(11):1905-13.
- 1039 64. Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, et al.
1040 Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat
1041 Commun. 2019;10(1):3193.
- 1042 65. Falcinelli SD, Peterson JJ, Turner AW, Irlbeck D, Read J, Raines SL, et al. Combined
1043 noncanonical NF-kappaB agonism and targeted BET bromodomain inhibition reverse HIV
1044 latency ex vivo. The Journal of clinical investigation. 2022;132(8).
- 1045 66. Li D, Dewey MG, Wang L, Falcinelli SD, Wong LM, Tang Y, et al. Crotonylation
1046 sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52. iScience.
1047 2022;25(1):103649.
- 1048 67. Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, et al. Histone
1049 Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and
1050 Pharmacological Actionability. Genes (Basel). 2020;11(5).

- 1051 68. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of
1052 latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase
1053 inhibitors. *AIDS (London, England)*. 2009;23(14):1799-806.
- 1054 69. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V. Ex Vivo Bioactivity
1055 and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells
1056 from Aviremic Patients. *Antimicrobial agents and chemotherapy*. 2015;59(10):5984-91.
- 1057 70. Banga R, Procopio FA, Cavassini M, Perreau M. In Vitro Reactivation of Replication-
1058 Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors. *Journal of virology*.
1059 2016;90(4):1858-71.
- 1060 71. Tsai P, Wu G, Baker CE, Thayer WO, Spagnuolo RA, Sanchez R, et al. In vivo analysis
1061 of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV
1062 infection. *Retrovirology*. 2016;13(1):36.
- 1063 72. Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM. Histone deacetylase inhibitors
1064 (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory
1065 complex also activate HIV transcription. *The Journal of biological chemistry*.
1066 2013;288(20):14400-7.
- 1067 73. Halsall JA, Turan N, Wiersma M, Turner BM. Cells adapt to the epigenomic disruption
1068 caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated
1069 transcriptional response. *Epigenetics Chromatin*. 2015;8:29.
- 1070 74. Chen FX, Smith ER, Shilatifard A. Born to run: control of transcription elongation by
1071 RNA polymerase II. *Nat Rev Mol Cell Biol*. 2018;19(7):464-78.

- 1072 75. Marsden MD, Loy BA, Wu X, Ramirez CM, Schrier AJ, Murray D, et al. In vivo
1073 activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and
1074 "kill" in strategy for virus eradication. *PLoS pathogens*. 2017;13(9):e1006575.
- 1075 76. Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, et al. Synthetic
1076 Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal. *Antimicrobial agents*
1077 *and chemotherapy*. 2018;62(11).
- 1078 77. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. Histone
1079 Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on
1080 Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing. *PLoS*
1081 *pathogens*. 2014;10(4):e1004071.
- 1082 78. Walker-Sperling VE, Pohlmeier CW, Tarwater PM, Blankson JN. The Effect of Latency
1083 Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for
1084 Human Immunodeficiency Virus Eradication. *EBioMedicine*. 2016;8:217-29.
- 1085 79. Bouchat S, Delacourt N, Kula A, Darcis G, Van Driessche B, Corazza F, et al. Sequential
1086 treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. *EMBO Mol*
1087 *Med*. 2016;8(2):117-38.
- 1088 80. Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, et al. An In-Depth
1089 Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1
1090 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral
1091 Gene Expression. *PLoS pathogens*. 2015;11(7):e1005063.
- 1092 81. Bui JK, Mellors JW, Cillo AR. HIV-1 Virion Production from Single Inducible
1093 Proviruses following T-Cell Activation Ex Vivo. *Journal of virology*. 2016;90(3):1673-6.

- 1094 82. Wedrychowski A, Martin HA, Li Y, Telwatte S, Kadiyala GN, Melberg M, et al.
1095 Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control. *Journal*
1096 *of virology*. 2023;97(1):e0125422.
- 1097 83. Moron-Lopez S, Telwatte S, Sarabia I, Battivelli E, Montano M, Macedo AB, et al.
1098 Human splice factors contribute to latent HIV infection in primary cell models and blood CD4+
1099 T cells from ART-treated individuals. *PLoS pathogens*. 2020;16(11):e1009060.
- 1100 84. Mota TM, McCann CD, Danesh A, Huang SH, Magat DB, Ren Y, et al. Integrated
1101 Assessment of Viral Transcription, Antigen Presentation, and CD8(+) T Cell Function Reveals
1102 Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency
1103 Reversal. *Journal of virology*. 2020;94(9).
- 1104 85. Walker-Sperling VE, Cohen VJ, Tarwater PM, Blankson JN. Reactivation Kinetics of
1105 HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific
1106 CD8+ T Cells. *Journal of virology*. 2015;89(18):9631-8.
- 1107 86. Kula A, Delacourt N, Bouchat S, Darcis G, Avettand-Fenoel V, Verdikt R, et al.
1108 Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined
1109 Disulfiram+Romidepsin Treatments. *Journal of acquired immune deficiency syndromes (1999)*.
1110 2019;80(5):605-13.
- 1111 87. Mbonye U, Leskov K, Shukla M, Valadkhan S, Karn J. Biogenesis of P-TEFb in CD4+ T
1112 cells to reverse HIV latency is mediated by protein kinase C (PKC)-independent signaling
1113 pathways. *PLoS pathogens*. 2021;17(9):e1009581.
- 1114 88. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The Fifth
1115 Edition of the Addiction Severity Index. *J Subst Abuse Treat*. 1992;9(3):199-213.

- 1116 89. Institute of Behavioral Research. Texas Christian University Drug Screen 5. Fort Worth:
1117 Texas Christian University, Institute of Behavioral Research (2020) [https://ibr.tcu.edu/forms/tcu-
1118 drug-screen/](https://ibr.tcu.edu/forms/tcu-
1118 drug-screen/) [
- 1119 90. Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, et al. A universal
1120 real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nature protocols.
1121 2008;3(7):1240-8.
- 1122 91. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A
1123 quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature.
1124 2019;566(7742):120-5.
- 1125 92. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches
1126 distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature
1127 medicine. 2014;20(4):425-9.
- 1128
- 1129
- 1130
- 1131
- 1132
- 1133
- 1134
- 1135
- 1136
- 1137
- 1138

1139 **Supplementary Figures Legends**

1140 **Supplementary Figure 1.** Substance use in the OPHION cohort. We assessed substance
1141 use by (a) clinical urine toxicology testing and (b) self-reported substance use questionnaires.
1142 Substance use results are separated by cohort groups by participant ID. Red squares indicate the
1143 presence of that substance in a urine sample; unavailable data were marked with “X” in a gray
1144 box. An expanded opiate panel was performed to assess for the presence of different opiate
1145 formulations. Color squares in panel b reflect any reported use by participants in the last 30 days.
1146 The numbers inside a given box indicate the number of days used this substance was reported to
1147 be used in the last 30 days. Gradient of color from blue to red indicate increasing report of use
1148 whereas white indicates no use. Concomitant use of alcohol, tobacco, marijuana, and gabapentin
1149 in the OPHION cohort was common. *all fentanyl measures were confirmed by follow-on
1150 quantification. Participants in the buprenorphine and methadone groups reported daily use of the
1151 respective medication in the 30 days prior, whereas participants taking opioids for chronic pain
1152 took opioids for 27-30 days in the 30 days preceding their enrollment in OPHION. 75% (N=3/4)
1153 of active injection users had urine toxicology screens positive for cocaine corresponding with
1154 self-report; all three reported smoking cocaine in the prior 30 days to specimen collection. One
1155 of twelve participants in the methadone use group and 2/12 in the non-opiate use group also has
1156 urine toxicology screens positive for cocaine. All active injection opioid users reported using
1157 multiple drugs on the same day in the last 30 days compared to 1/12 participants in non-opioid
1158 use group and 10/20 participants in methadone, buprenorphine and prescription opiate use
1159 groups combined. N=3/4 active injection opioid users reported smoking marijuana in the last 30
1160 days. 6 and 8 participants about the 12 participants in opioid use groups had urine toxicology
1161 screens positive for benzodiazepines and gabapentin; all but 1 in both cases reported that this

1162 substance was prescribed. No participant had urine toxicology screens positive for amphetamines
1163 or barbiturates. All participants injecting opioids used tobacco in the preceding 30 days and,
1164 overall, 23 of 36 OPHION participants used tobacco within the month prior to their blood
1165 collection. 25% (N=6/24) of opioid use participants consumed alcohol in last 30 days compared
1166 to 58% (7/12) in the control group.

1167

1168 **Supplementary Figure 2.** HIV-1 LRA boosting response in the OPHION cohort by subgroup
1169 analysis. (a) HIV-1 fold-increase in unspliced RNA transcription plotted as a function of self-
1170 reported Hispanic (dark purple circles) or non-Hispanic (light blue circles) ethnicity. (b) Opioid-
1171 use subgroup analysis highlighting LRA response to α CD3/ α CD28 beads from Main Fig 1a, as a
1172 function of opioid use subgroup. Means and SEM are shown. Dotted horizontal line denotes a
1173 fold-change of 1. ** $p < 0.01$ for LRA combinations, corrected for multiple comparisons.
1174 α CD3/ α CD28, anti-CD3 anti-CD28 superparamagnetic beads; RMD, romidepsin; PNB,
1175 panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM.

1176

1177

1178 **Supplementary Figure 3.** Flow cytometry gating strategies. Representative intracellular
1179 cytokine staining plots for (a) control and (b) α CD3/ α CD28 bead-exposed PBMC are shown. (c)
1180 Gating strategy for the three AIM assays. A representative sample exposed to TCR agonism is
1181 shown.

1182

1183 **Supplementary Figure 4.** LRA-induced immune activation as a function of opioid use. Results
1184 obtained with the (a) OX40/PD-L1, (b) OX40/CD25, and (c) CD69/CD40L AIM assays are

1185 reported for all ten conditions in the LRA panel, where samples from participants with (blue
1186 circles) and without (yellow circles) opioid use are shown. Data are represented as means \pm 95%
1187 CIs. For the OX40/PL-L1 assay, the highest measured levels in OX40/PDL1 assay with
1188 bryostatin 1nM, R+B, and P+B are the same non-opioid-using participant. (d) Individual data
1189 points for CD69⁺ live total CD4⁺ T cells, as a function of opioid use. (e) Comparative
1190 hierarchies of intracellular cytokine production in CD4⁺ and CD8⁺ T cells exposed to TCR
1191 agonism (α CD3/ α CD28 beads). Data displayed in these panels are identical to the data values
1192 shown in Main Fig. 3. *p<0.05, ** p<0.01, **** p<0.0001, corrected for multiple comparisons.
1193 TNF, tumor necrosis factor alpha; IFN, interferon gamma; IL-2, interleukin-2; CD4, CD4⁺ T
1194 cells; CD8, CD8⁺ T cells.

1195
1196 **Supplementary Figure 5.** Histone acetylation effects during LRA boosting, as a function of
1197 opioid use. Using the same data displayed in Main Fig. 4, here we show individual data points,
1198 labelled as samples from participants with (blue circles) and without (yellow circles) opioid use.
1199 (a) The proportion of live total CD4⁺ T cells with acetylated histone H3, assessed by flow
1200 cytometry, (b) Mean fluorescence intensity (MFI) of acetylated histone H3 per live total CD4⁺ T
1201 cells.

1202
1203 **Supplementary Figure 6.** The effects of LRA boosting on human reference gene transcription.
1204 Using leukapheresis samples from HEAL participants (n=10), we assessed and compared fold-
1205 changes in transcription of three host genes: (a) IPO8, (b) TBP, and (c) UBE2D2. Reference
1206 gene multiplexing was validated for (d) TBP and (e) UBE2D2 quantifications. The rationale to
1207 study these three reference genes is as follows. IPO8 transcription is used as an internal control

1208 by the AIDS Clinical Trials Group's Virology Specialty Laboratories to measure RNA integrity
1209 in a dichotomous way. IPO8 Ct values >27 are used to suggest degradation of cellular samples in
1210 storage, and samples with IPO8 Ct >27 do not report HIV-1 RNA values. Recent work by
1211 Nancie Archin's group at the UNC HIC Cure Center identified TBP and UBE2D2 as two of the
1212 more stable host genes during their LRA exposures, which included PMA, AZD5582, and
1213 HDACi, among a panel of eight LRA.

1214

1215 **Supplementary Figure 7.** The effects of LRA boosting on human reference gene transcription.
1216 Using leukapheresis samples from HEAL participants (n=9), we assessed and compared fold
1217 changes in transcription of three host genes: (a) IPO8, (b) TBP, and (c) UBE2D2. Reference
1218 gene multiplexing was validated for (d) TBP and (e) UBE2D2 quantifications. The rationale to
1219 study these three reference genes is as follows. IPO8 transcription is used as an internal control
1220 by the AIDS Clinical Trials Group's Virology Specialty Laboratories to measure RNA integrity
1221 in a dichotomous way. IPO8 Ct values >27 are used to suggest degradation of cellular samples in
1222 storage, and samples with IPO8 Ct >27 do not report HIV-1 RNA values. Recent work by
1223 Nancie Archin at the UNC HIV Cure Center identified TBP and UBE2D2 as two of the more
1224 stable host genes during LRA exposures, which included PMA, AZD5582, and HDACi, among a
1225 panel of eight LRA.

1226

1227 **Supplementary Figure 8.** Variance in LRA response. (a) Magnitude of HIV-1 caRNA
1228 transcription fold-changes in biological replicate LRA experiments performed with HEAL
1229 leukapheresis samples, using the same data as shown in Main Fig 5a-c, (b) Box and whiskers
1230 plot displaying the data of Fig. 5g as the mean (solid black horizontal line), inter-quartile range

1231 (25th – 75th percentiles denoted as the borders of the vertical rectangle), and 5th-95th percentiles
1232 (whiskers, error bars). Values below and above the whiskers are shown as individual data points.
1233 PMA-iono, PMA with ionomycin; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P,
1234 PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM.

1235





1236 **Supplementary Tables**

1237 **Supplementary Table 1** – Breakdown of OPHION cohort into opioid use subgroups

1238 **Supplementary Table 2** – HEAL Participant Characteristics

1239

1240

a.**b.****c.****d.****Figure 1**







Figure 2






Figure 3

Figure 4


a.




b.




c.



d.



e.






Figure 5








Figure 6